Abstract

Sanjay Jana*, Ashrubindu Bhunia and Dr. Beduin Mahanti

ABSTRACT

Nowadays, most of fungal infections such as candidiass can range from superficial mucous membrane infection to life threatening systemic mycoses. Candida infections give significant clinicalproblem globally due to most rapid rise in compromised host populations including HIV/AIDS, organ transplant recipients, and patients those are on chemotherapy. In addition to this, a sharp increase in the aging populations which are susceptible to fungal infections is expected in next few decades. Antifungal drugs for these problems are relatively difficult to develop compared to the antibacterial drugs owing to the eukaryotic nature of the cells. Therefore, only a handful of antifungal agents arecurrently available to treat the myriad of fungal infections. Moreover, the rising antifungal resistance and host-related adverse reactions have limited the antifungal arsenal against fungal pathogens.